Myeloid neoplasm

This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …

This study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …

This Phase 3 trial is testing whether a new drug called mezigdomide, combined with two standard drugs (bortezomib and dexamethasone), works better than the current standard combination (pomalidomide, bortezomib, and dexamethasone) for people with multiple myeloma that has come ba…

This study tests whether adding the drug iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has relapsed or become resistant. About 88 participants will receive either the new combo or the standard combo…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…

This phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…

This phase 2 trial is testing a combination of two drugs—CM336 (a bispecific antibody) and isatuximab (a monoclonal antibody)—in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function…

This study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This phase 2 trial tests whether giving olutasidenib with azacitidine, followed by olutasidenib alone as maintenance, can keep acute myeloid leukemia (AML) with an IDH1 mutation from returning. The study enrolls 28 adults who have already achieved remission after initial treatmen…

This early-stage trial tests an experimental cell therapy called IBR733 for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy involves giving immune cells by vein in repeated cycles. The main goals are to check safety, …

This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This early-phase trial is testing whether adding the drug emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity stem cell transplant. Emapalumab blocks a protein …

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This study follows about 665 people with myelodysplastic syndromes, beta-thalassemia, or myelofibrosis who have already taken luspatercept in earlier trials. Researchers want to see how safe the drug is over many years by tracking side effects, disease progression, and survival. …

This study tests a new drug called elranatamab for people with multiple myeloma that has returned or stopped responding to treatment. Half of the 492 participants will get elranatamab as a weekly shot; the other half will get one of several standard drug combinations. The goal is…

This study tests a new drug, linvoseltamab, alone or with another drug called carfilzomib, against standard treatments for people with multiple myeloma that has returned or not responded to prior therapy. About 915 participants who have had 1 to 3 prior treatments will be enrolle…

This early-stage study tests a new drug called KK2845 for adults whose acute myeloid leukemia (AML) has returned or not improved after standard treatments. The goal is to find a safe dose and see how well the body tolerates it. About 72 participants will take part in two phases: …

This study tests a medicine called Xolatryp in adults who have had a severe heart attack (STEMI) and are getting a procedure to open blocked arteries. Participants receive either a single 6-hour infusion of Xolatryp or a placebo, and their heart health is monitored for 30 days. T…

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. The goal is to keep providing the treatment while monitoring for any side effects. About 80 participants will take part, and th…

This study tests a two-drug combination (tagraxofusp and venetoclax) in adults with a rare and aggressive blood cancer called BPDCN who have not had prior treatment. The main goal is to see if the combination can achieve complete remission after 3 months. Depending on results, pa…

This study tests a combination of four drugs, called CLAG-GO, in adults whose acute myeloid leukemia (AML) has not responded to standard treatment or has come back after remission. Participants receive the drugs during a hospital stay, and if the cancer goes into remission, they …

This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …

This study tests a new way to prepare donor stem cells (called Orca-Q) for people with blood cancers like leukemia or MDS who need a transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells with fewer complications. About 300 partici…

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This early-phase trial is testing a new oral drug called BG-75202, alone or with another medicine, in about 118 adults with myeloid blood cancers that have come back or not responded to prior treatment. The main goals are to check safety, find the right dose, and get a first look…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This phase 3 trial tests whether adding the drug sapablursen to standard treatment helps people with polycythemia vera, a blood disorder causing too many red blood cells. About 250 participants who currently need regular blood removal (phlebotomy) will receive either sapablursen …

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About 26…

This study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to attack two targets (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has returned or stopped responding to prior treatments. The study compares AZD0120 t…

This phase I trial tests whether adding the experimental drug iadademstat to two standard leukemia medications (azacitidine and venetoclax) is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. Iadademstat bl…

This study is testing an oral medication called asciminib in children aged 1 to 18 with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML-CP) who have already tried other treatments. The goal is to find the right dose that works as well as it does in adults and t…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This study tests whether giving antibody replacement therapy can reduce serious infections in people who have received CAR-T cell therapy for blood cancers. CAR-T therapy often lowers the body's natural antibodies, raising infection risk. The trial will compare the antibody treat…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This early-phase trial tests whether giving anti-CD19 CAR T cells together with a half-matched bone marrow transplant can safely treat aggressive blood cancers like leukemia and lymphoma. About 155 adults aged 18 to 75 with CD19-positive cancers will receive the combined therapy …

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This study tests a new drug called mRNA-2808 in people with multiple myeloma that has returned or not responded to standard treatments. The drug is given through a vein and aims to control the cancer. The trial will check for side effects and measure how well the drug works. Abou…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immu…

This early-phase trial tests a new treatment called CD64 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target and attack leukemia cells. The m…

This large Phase 3 trial is testing whether adding the experimental drug ziftomenib to standard chemotherapy helps people with untreated acute myeloid leukemia (AML) who have specific genetic mutations. About 1,300 participants will be randomly assigned to receive either ziftomen…

This program provides expanded access to the experimental drug ziftomenib for adults with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). It is for patients who have exhausted standard …

This study tests whether adding the drug belumosudil to standard care can better prevent graft-versus-host disease (GVHD) in adults with blood cancer who have had a stem cell transplant. About 46 participants will receive belumosudil along with their usual GVHD prevention medicin…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a new drug, asciminib, as the first treatment for adults newly diagnosed with chronic myeloid leukemia (CML). If the drug alone does not achieve a deep response within 2 to 3 years, a low dose of another targeted therapy is added. The goal is to see if this appro…

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…

This study is observing 50 patients with relapsed or refractory multiple myeloma who are taking melflufen plus dexamethasone as a later-line treatment. The goal is to see how well the drug controls the disease in routine medical practice, outside of a controlled trial. Researcher…

This phase 3 trial is testing a new CAR-T cell therapy called arlo-cel against standard treatments for adults with multiple myeloma that has come back or stopped responding to previous therapies. About 440 participants will receive either arlo-cel or a standard regimen. The study…

This study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the …

This pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Par…

This phase 2 trial tests whether a combination of iberdomide (a pill) and daratumumab (an injection) can eliminate leftover cancer cells in multiple myeloma patients who still have minimal residual disease after a stem cell transplant. About 60 participants will receive up to 26 …

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This early-phase trial tests a drug called DR-18 in 40 adults with acute myeloid leukemia or myelodysplastic syndrome whose cancer returned or persisted after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against cancer c…

This phase 3 trial compares bomedemstat, an experimental oral drug, to hydroxyurea (standard therapy) in 300 people with essential thrombocythemia who have not yet received cytoreductive treatment. The goal is to see if bomedemstat better controls platelet counts and prevents com…

This phase 2 trial tests whether injecting chemotherapy drugs (cytarabine, methotrexate, and hydrocortisone) into the spinal fluid can prevent severe brain side effects in people receiving CAR T-cell therapy for blood cancers. About 20-70% of CAR T patients develop neurotoxicity,…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndromes. The study will enroll 3…

This trial tests a new drug called DS3790a for people with certain blood cancers, including B-cell non-Hodgkin lymphoma. The drug is designed to find and attack cancer cells while sparing healthy ones. The study will check safety and how well it works in about 420 adults.

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…

This early-stage trial tests a combination of four drugs—iberdomide, daratumumab, elotuzumab, and dexamethasone—in people whose multiple myeloma has come back after treatment. The study has two phases: first, finding the safest dose of iberdomide, and second, seeing how well the …

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This early-stage trial tests a personalized dendritic cell vaccine in 10 multiple myeloma patients who are already in very good remission. The vaccine is designed to train the immune system to keep the cancer from returning. The main goal is to see if the vaccine is safe, with a …

This study tests whether a new drug combination (elranatamab, daratumumab, and lenalidomide) works better than a standard combination for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The trial involves about 1,116 participants and …

This Phase 3 trial tests three different drug combinations for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The goal is to see which combination leads to the deepest remission (measured by minimal residual disease negativity) after 18 …

This early-stage trial tests a new treatment called CD4CAR T cells for people with chronic myelomonocytic leukemia (CMML) that has come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells.…

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…

This phase 3 trial tests whether adding the drug revumenib to standard intensive chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (NPM1 mutation). About 468 participants will receive either revumenib or a placebo along…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This program provides the investigational drug bezuclastinib to adults with systemic mastocytosis who have failed or cannot tolerate standard treatments. Participants must be at least 18 years old and able to swallow tablets. The goal is to offer a potential treatment option when…

This study tests a new type of immunotherapy called CAR T cells that are designed to recognize several different targets on multiple myeloma cancer cells. The treatment involves taking a patient's own immune cells, modifying them in a lab to better attack the cancer, and infusing…

This phase II trial is for older adults with a specific type of acute myeloid leukemia (AML) that has IDH gene mutations. Researchers want to find out whether starting treatment with an IDH-targeted drug (ivosidenib or enasidenib) followed by standard therapy (azacitidine plus ve…

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-phase trial tests a new type of cell therapy for people with relapsed or refractory acute myeloid leukemia (AML). The treatment uses a patient's own immune cells, engineered to recognize six different targets on leukemia cells. The study aims to see if this approach is…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adult…

This early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can control the disease as a first treatment. About 20 participants will…

This study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells …

This study is testing an experimental drug called surzetoclax, alone or combined with other cancer drugs, in about 130 adults with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if it can shrink or control…

This early-phase trial is testing a combination of two drugs—Hyper-CVAD chemotherapy and venetoclax—in 22 children and young adults whose leukemia has returned or not responded to treatment. The main goal is to find a safe dose and monitor side effects. If the combination proves …

This study tests whether a new pill (gecacitinib) plus a weekly injection (pegylated interferon) can help people with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to bring blood counts back to normal and ease symptoms. Thirty adults wi…

This early-phase trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in 24 adults with advanced blood cancers (like leukemia or MDS) receiving stem cell transplants from partially matched donors. The main goal is to se…

This early-phase trial is testing a new type of CAR T-cell therapy, called CD4CAR, in people with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The therapy targets a protein called CD4 on leukemia cells. The goal is to safely eliminate as…

This study tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd)—in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see how well the regimen controls the disease and what si…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This early-stage trial is testing a new type of cell therapy called universal CAR-T cells for people with multiple myeloma that has not been cured by standard treatments. The therapy uses donor cells modified to target myeloma cells, aiming to be a ready-made option. The study wi…

This early-phase study is testing a new drug called rebecsinib in 28 people whose secondary acute myeloid leukemia or high-risk myelofibrosis has come back or not responded to treatment. The drug is given by IV infusion four times per 28-day cycle for up to six cycles. The main g…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can impr…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This early-stage trial is testing a new drug called JNJ-79635322 in combination with other myeloma treatments (daratumumab, lenalidomide, or pomalidomide) in 140 people with multiple myeloma. The main goal is to find a safe and effective dose and to see how well the body tolerate…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests an experimental drug called elenestinib (BLU-263) in people with indolent systemic mastocytosis, a rare condition where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 534 participants will receive either the drug or a placebo…

This trial investigates whether luspatercept can treat anemia caused by chemotherapy in adults with low-risk acute myeloid leukemia (AML). Participants receive luspatercept injections after chemotherapy, and researchers monitor hemoglobin levels and safety. The study aims to find…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults who have already achieved remission after initial treatment…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-phase trial is testing a new drug called BL-M11D1 in 120 adults with acute myeloid leukemia that has come back or not responded to standard treatments. The drug is designed to target and deliver a toxin directly to leukemia cells. The main goals are to check safety, fi…

This early-phase trial is testing whether adding the drug daratumumab to standard chemotherapy can help adults aged 60 and older with a high-risk form of acute myeloid leukemia (AML). The main goal is to find the safest dose of daratumumab when given alongside chemotherapy. The s…

This early-phase trial tests a combination of CAR T cells that target three different markers (CLL-1, CD33, and CD123) on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. The study aims to see if this approach is safe and can shrink tumors. Only 10 p…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This early-stage trial is testing whether adding roginolisib to the standard drug ruxolitinib is safe and tolerable for adults with myelofibrosis whose disease no longer responds to JAK inhibitors. The study will enroll 26 participants and monitor side effects, heart changes, and…

This phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CL…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial tests whether combining the drugs gilteritinib with ivosidenib or enasidenib is safe for people with acute myeloid leukemia (AML) that has returned or not responded to treatment. Participants must have specific gene mutations (FLT3 and IDH1 or FLT3 and IDH2…

This study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the …

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests a new experimental drug called EP0042 in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The goal is to find a safe dose that might work against the cancer, either alone or with other treatments. About 70 participants will take part to…

This early-stage trial tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This study tests two different doses of the drug quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission after initial treatment and have not had a stem cell transplant. The goal …

This phase 2 trial tests the drug pacritinib in 30 people with myelofibrosis, a rare bone marrow cancer, who also have low platelet counts. The goal is to see if pacritinib can reduce scarring (fibrosis) in the bone marrow and improve symptoms. Participants take pacritinib pills …

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and se…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This phase 3 trial tests whether adding the targeted drug inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study will enroll about 6,000 participants an…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…

This early-phase trial tests a drug called CRD3874-SI, which activates the STING pathway to boost the immune system's ability to fight cancer cells. It is for people with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to f…

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to see if the combination is safe and can shrink tumors b…

This Phase 3 trial tests whether mocravimod, taken as a pill, can prevent acute myeloid leukemia (AML) from returning after a stem cell transplant. About 366 adults with high-risk AML will receive either mocravimod or a placebo for up to two years. The main goal is to see if the …

This study tests an experimental drug called linvoseltamab in 220 people with AL amyloidosis that has returned or not improved after prior therapy. The drug aims to reduce abnormal proteins that damage organs like the heart and kidneys. The trial first finds the safest dose, then…

This early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…

This early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…

This study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-stage trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (like AML or MDS) came back after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into remission.…

This early-phase trial tests whether specially trained natural killer (NK) cells, called CIML NK cells, along with interleukin-2 (IL-2), can safely prevent leukemia from coming back after a stem cell transplant. The study enrolls 15 adults with high-risk acute myeloid leukemia, m…

This early-stage trial tests a new drug, 8-chloro-adenosine, combined with the existing drug venetoclax in 30 adults with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to check safety and find the best dose. Researchers hope this combin…

This phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…

This phase 3 trial compares a four-drug combination (daratumumab, bortezomib, lenalidomide, and dexamethasone) against a three-drug regimen (daratumumab, lenalidomide, and dexamethasone) in 1,450 people with newly diagnosed multiple myeloma who are not candidates for early stem c…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This early-phase study tests a new drug called SL-401 combined with two other drugs (azacitidine and venetoclax) in people with certain blood cancers—acute myeloid leukemia, myelodysplastic syndrome, and blastic plasmacytoid dendritic cell neoplasm. The main goal is to find the s…

This large phase 3 trial is testing whether a new formulation of two chemotherapy drugs (CPX-351) and a targeted drug called gilteritinib can improve outcomes for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study compares these new approaches …

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This study tests a new chemotherapy drug, L-Annamycin, combined with standard cytarabine in adults with acute myeloid leukemia (AML) that has come back or not responded to first treatment. About 312 participants will receive either the new drug combo or a placebo plus cytarabine.…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment combines specially trained natural killer (NK) immune cells with a drug called atezolizumab. The main goal is to find a…

This phase 2 study tests whether the drug ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either ivosidenib or a placebo daily. The main goal is to see if the d…

This early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…

This study tests whether adding daratumumab to standard lenalidomide and dexamethasone can improve survival in people with high-risk smoldering myeloma, a condition that often progresses to active cancer. About 288 participants will receive either the standard two-drug regimen or…

This early-phase trial is testing a new drug called miRisten in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to prior treatments. The drug works by blocking a molecule that helps cancer cells grow. The main goal is to check safety and find the best …

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This early-phase study is testing an experimental oral drug called AZD3632 in about 84 people with advanced blood cancers (acute leukemias or myelodysplastic syndromes) that have certain genetic changes. The main goals are to check the drug's safety and find the right dose, while…

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study tests a new way of giving the drug elranatamab to people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if giving the drug less often and outside the hospital can reduce side effects and hospital stays. About 40 a…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best…

This Phase 2 trial is testing whether adding cyclophosphamide to elranatamab helps people with relapsed or refractory multiple myeloma who have risk factors that make standard treatment less effective. About 26 participants will receive the combination therapy. The main goal is t…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This umbrella trial tests the drug isatuximab (Sarclisa) combined with several newer agents, with or without dexamethasone, in adults whose multiple myeloma has returned or stopped responding to at least two prior treatments. About 258 participants will be assigned to different s…

This Phase 2 trial is testing an investigational drug called linvoseltamab in 116 people with precancerous blood conditions that raise their risk of developing multiple myeloma. The goal is to see if the drug can eliminate abnormal plasma cells and lab signs of disease. Researche…

This Phase 2 trial tests STP938, a daily pill, in 50 adults with high-risk essential thrombocythaemia who cannot use standard therapy. The goal is to see if it safely lowers high platelet counts and reduces complications like blood clots. Participants take the drug for up to 12 m…

This study tests a new oral drug, QTX-2101, combined with standard ATRA therapy for adults newly diagnosed with a low-risk form of acute promyelocytic leukemia (APL). The goal is to see if the oral capsule works as well as the current intravenous treatment. About 150 participants…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This early study tests a new treatment called RN1201 for people newly diagnosed with multiple myeloma, a type of blood cancer. RN1201 uses specially engineered immune cells from a healthy donor to target and kill cancer cells. Participants receive a single infusion of these cells…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This early-stage trial tests a cell therapy called vididencel in 24 adults with chronic myeloid leukemia (CML) who still have traces of cancer despite taking standard medication. The goal is to see if adding vididencel to their current treatment is safe and might eventually allow…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This early-stage trial tests an oral drug called AG-120 in people with advanced blood cancers, like acute myeloid leukemia, that have a specific IDH1 mutation. The study aims to find the safest dose and see if the drug can control the disease. About 291 participants will take the…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This study tests a new combination of drugs (venetoclax, azacitidine, chidamide, and others) against the standard chemotherapy for adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). The goal is to see if the new combo leads to more remissions and fewer side effe…

This phase 1 trial is testing a new way to dose the chemotherapy drug melphalan for people with multiple myeloma who are getting a stem cell transplant. Instead of a standard dose, the amount is personalized based on each patient's blood levels after a test dose. The goal is to f…

This study tests whether giving anti-thymocyte globulin (ATG) based on individual patient levels can reduce viral infections after stem cell transplants from unrelated donors. About 324 patients will receive either personalized or fixed doses of ATG. The goal is to find a dose th…

This early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects an…

This study tests an experimental drug called etentamig combined with daratumumab in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 660 participants will receive either the new combination or standard treatment. The goal is to s…

This study is for people with a high-risk form of smoldering multiple myeloma, an early stage of blood cancer. The purpose is to test a drug called belantamab mafodotin to find the safest dose and see if it can control the disease. About 30 participants will receive the drug, and…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study is testing a new way to do stem cell transplants for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). It combines stem cells from a half-matched donor (haploidentical) with cord blood, given at different times. The goal is to help …

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This early-phase trial is testing a new cell therapy called CD83 CAR T cells in 26 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack a protein (CD83…

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-phase trial tests whether adding natural killer (NK) cells from a healthy donor to the standard drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML). About 32 adults with relapsed or hard-to-treat AML will receive the combination. The main goa…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-stage trial is testing a new drug called cirtuvivint, alone or with another drug combo (ASTX727), in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and check for side effects. About 54 participants whose…

This early-stage study is testing whether a combination of two drugs—elranatamab (given as a shot) and iberdomide (taken as a pill)—is safe and tolerable for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial will enroll about 87 p…

This early-phase trial is testing a combination of two oral drugs—venetoclax and decitabine/cedazuridine—in children and teens whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. The study aims to find the safest dose and check for early signs tha…

This early-phase trial tests a combination of three drugs—ziftomenib, venetoclax, and gemtuzumab—in children and young adults (ages 3 to 21) with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effec…

This study tests a program called PASCA that helps doctors detect and manage complications like high blood pressure, kidney failure, chronic pain, and fatigue in multiple myeloma patients after a stem cell transplant. About 204 adults aged 18 to 70 will be randomly assigned to ei…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

This phase III trial is testing three different drug combinations for people newly diagnosed with multiple myeloma who are considered frail or intermediate-fit and are not getting a stem cell transplant. The study compares three-drug induction regimens followed by either double o…

This phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…

This study follows people with chronic myeloid leukemia (CML) who have already benefited from the drug asciminib in earlier Novartis trials. Researchers want to see how safe the drug is over the long term. About 347 participants will continue taking asciminib or other similar dru…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This study combines three chemotherapy drugs (cladribine, idarubicin, cytarabine) with a targeted drug (quizartinib) to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It includes up to 80 adults who are newly diagnosed or whose cancer has returne…

This study is watching how well asciminib works and how safe it is in adults with a type of blood cancer called chronic myeloid leukemia. It includes people who are newly diagnosed or have already tried one other treatment. The main goal is to see how many patients reach a very l…

This early-phase study tests a new form of curcumin (the active ingredient in turmeric) that is wrapped in tiny fat particles to help the body absorb it better. The goal is to find the safest dose for people with multiple myeloma that has come back or stopped responding to standa…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This study tests whether giving the drug belantamab mafodotin less often, combined with other standard cancer medicines, can still control multiple myeloma while reducing side effects like eye problems. About 200 adults whose cancer has returned or stopped responding to prior tre…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This study tests a combination of three drugs—ASTX727, venetoclax, and gilteritinib—for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome that has a FLT3 mutation. The drugs work in different ways to stop cancer cells from growing. The trial aims to f…

This trial is for people newly diagnosed with a high-risk form of multiple myeloma, a blood cancer. It tests several new drug combinations to see which works best at killing cancer cells and keeping the disease from coming back. About 300 participants will receive different treat…

This early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…

This early-stage trial tests whether adding a drug called NT-I7 (a lab-made immune booster) can help CAR-T cells survive longer in people with multiple myeloma that has come back or stopped responding to treatment. About 52 participants who are already getting standard CAR-T ther…

This study tests a new treatment for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to recognize and attack cancer cells…

This study tests whether combining two drugs, teclistamab and daratumumab, can help people newly diagnosed with both multiple myeloma and light chain amyloidosis. About 30 adults will receive the treatment for up to 24 cycles. The goal is to see if the combo improves survival wit…

This study tests a combination of two drugs, CPX-351 and ivosidenib, in about 30 adults with a specific genetic form of acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if the combo can shrink or control the cancer. Participants must have the IDH1 …

This phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…

This phase 2 study tests asciminib, a daily pill, in 40 adults with chronic myeloid leukemia whose first treatment with a TKI drug didn't work or caused side effects. Participants take asciminib for up to 2 years. The main goal is to see how many achieve a major molecular respons…

This Phase 2 trial tests whether adding venetoclax to a chemotherapy regimen of cladribine, low dose cytarabine, and azacitidine can improve remission rates in adults aged 50 and older with untreated acute myeloid leukemia. The study involves 145 participants and uses a two-stage…

This study tests whether the drug selinexor can safely extend the benefits of CAR-T cell therapy in people with high-risk multiple myeloma that has returned after other treatments. About 20 participants will take selinexor pills after their CAR-T infusion. The goal is to see if t…

This early-phase trial tests whether stem cell transplants from donors whose tissue type does not fully match the patient can be safe and effective for people with blood cancers who have no other donor options. About 29 adults aged 18-60 will receive chemotherapy followed by the …

This study tests a new oral drug called bleximenib for people with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes in the cancer cells. The trial has two phases: first to find the safest dose, then to see how well it work…

This phase 2 trial is testing whether adding isatuximab to the standard drug lenalidomide after a stem cell transplant can better control high-risk multiple myeloma. About 61 adults aged 18 to 72 with newly diagnosed high-risk myeloma will receive the combination as maintenance t…

This early-phase trial is testing a new type of gene therapy called CAR 70-BCMA dual-target CAR-T for people with relapsed or refractory plasma cell neoplasms, including multiple myeloma. The therapy involves taking a patient's own immune cells, re-engineering them to recognize a…

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tum…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This study tests a new combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults with newly diagnosed acute myeloid leukemia (AML). About 30 participants will receive this therapy, followed by standard chemotherapy and, for…

This study tests whether combining two drugs, blinatumomab and asciminib, can help control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The trial enrolls 40 adults who are not good candidates for strong chemotherapy. Researchers will monitor safety and…

This Phase 2 trial tests the drug asciminib in 50 adults newly diagnosed with chronic myeloid leukemia (CML). The goal is to see if asciminib can control the disease and to check for side effects. Participants take the drug by mouth, and researchers monitor their health closely.

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…

This study tests several combinations of the experimental drug QLS32015 with other medicines in 160 people whose multiple myeloma has come back or stopped responding to prior therapy. The goal is to see which combination works best to shrink tumors and achieve deep remission. Par…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …

This early-stage trial tests an experimental oral drug called KTX-1001 in people with multiple myeloma that has returned or not responded to prior treatments. The drug works by blocking a protein that helps myeloma cells grow. The study will enroll 165 adults and will also test K…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This early-stage study tests a new drug called BL-M24D1 in about 33 adults with multiple myeloma or other blood cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug helps control the disease. Particip…

This study tests whether alternating two different drug combinations can help control higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). About 60 adults who have not responded to or relapsed after standard treatment will receive cladribine, low…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This early-stage study tests a new drug called JNJ-88549968, a bispecific antibody designed to direct the body's immune T cells to attack cancer cells with a specific CALR mutation. The trial will enroll about 220 adults with essential thrombocythemia or myelofibrosis who carry t…

This study tests two new drug combinations (Tec-DR and Tal-DR) against a standard treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if the new combos keep the cancer from growing longer and help more patients ach…

This study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. The trial enrolls 600 adults aged 18 and older who h…

This phase 3 study compares a new injectable drug, JNJ-79635322, to an existing one, teclistamab, in about 700 people with multiple myeloma that has returned after 1 to 3 prior treatments. The goal is to see which drug works better at shrinking tumors and delaying disease progres…

This study tests a new drug called talquetamab in people with multiple myeloma that has come back or stopped responding to treatment. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to find the best dose and see how well…

This study tests a new all-oral combination of three drugs—SNDX-5613, ASTX727, and venetoclax—for people with acute myeloid leukemia (AML) or related leukemia. The first part finds the safest dose of SNDX-5613, and the second part checks if that dose helps control the disease. Ab…

This early-stage trial is testing an experimental drug called JNJ-95804306 in people with blood cancers like leukemia that have come back or not responded to standard treatments. The study has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors whe…

This study provides ongoing access to daratumumab-based treatment for 500 adults with multiple myeloma who are already benefiting from it in earlier Janssen trials. The main goal is to monitor long-term safety, including serious side effects and infections. Participants continue …

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This phase 3 study compares two new drug combinations (talquetamab plus pomalidomide or talquetamab plus teclistamab) against standard treatments for multiple myeloma, a blood cancer. About 795 participants will be randomly assigned to one of the groups. The goal is to see which …

This study tests whether adding the drug teclistamab to standard maintenance therapy (lenalidomide) can help keep multiple myeloma from coming back after a stem cell transplant. About 1,600 adults with newly diagnosed myeloma who have already responded to initial treatment will b…

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This early-phase study tests a new drug called SHR-3836 in 99 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors. Parti…

This study tests the safety of teclistamab, a drug given as a shot, in 75 Indian adults with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see how safe it is in routine practice. Participants must have tried specific prior…

This study follows 295 multiple myeloma patients who previously received cilta-cel (a CAR-T cell therapy) to track long-term side effects. No new treatment is given. Researchers will monitor for new cancers, nerve disorders, autoimmune issues, and infections over time. The goal i…

This study tests a new drug, JNJ-79635322, against another antibody treatment in people with multiple myeloma that has come back or stopped responding after at least three prior treatments. About 400 participants will be randomly assigned to one of the two treatments. The goal is…

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This early-phase study tests whether giving sirolimus before standard bispecific antibody therapy can improve T-cell function and treatment response in people with multiple myeloma. About 10 participants will receive sirolimus first, then the antibody treatment. The main goals ar…

This early-phase trial tests whether high-dose vitamin C, combined with a lower dose of the chemotherapy drug melphalan and a stem cell transplant, is safe and effective for people with relapsed multiple myeloma. The study enrolls 18 adults who have already tried at least three p…

This study tests an experimental drug called JNJ-79635322 in people with multiple myeloma that has returned or stopped responding after at least 3 prior treatments. The goal is to see how well the drug shrinks or controls the cancer. About 157 participants will receive the drug a…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researc…

This phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant w…

This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…

This study will test a new type of PET/CT scan that uses a special tracer to find BCMA, a protein on myeloma cells. The goal is to see if this scan can more accurately detect active myeloma throughout the body compared to standard methods. About 300 people with suspected or known…

This early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those wh…

This early-stage study tests a new radioactive tracer called [89Zr]DFO-YS5 for PET scans to find multiple myeloma cells that have a specific protein (CD46). About 20 adults with confirmed multiple myeloma will receive the tracer and have a PET scan. The goal is to see if this met…

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…

This pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…

This study tests whether yoga and mindfulness programs can improve quality of life, reduce inflammation, and even affect gene activity in people who have survived lung, colon, or non-Hodgkin's lymphoma cancer. One hundred survivors, at least six months past treatment, will be ran…

This study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study tests two oral medications—diosmin-hesperidin (a flavonoid supplement) and loratadine (an allergy drug)—to prevent bone pain caused by G-CSF, a drug that boosts white blood cells in blood cancer patients. Researchers will compare each drug alone and in combination agai…

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This pilot study tests whether a virtual mindfulness-based stress reduction (MBSR) program can improve mental health in cancer patients living in underserved or rural parts of Minnesota. About 45 participants will take the online course and report changes in stress, anxiety, and …

This study tests whether a diet low in added sugar, high in fiber, and rich in omega-3s (called LASO-3) can help reduce nerve pain, numbness, and tingling caused by chemotherapy. Fifty cancer survivors who finished chemo at least three months ago will receive virtual nutrition co…

This study tests a program called Step Up that combines in-person coaching with a mobile app to teach coping skills and encourage physical activity. It includes 177 adults who have had a stem cell transplant or CAR-T therapy for blood cancers like leukemia or multiple myeloma. Th…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…

This study looks at whether a custom website can improve quality of life for people with multiple myeloma. About 108 adults with newly diagnosed or returning myeloma will use the platform to report side effects and get personalized tips. The goal is to see if this digital support…

This study tests whether carefully timed lighting can help multiple myeloma patients undergoing their first stem cell transplant. Two hundred participants will receive either bright morning light and dim evening light, or dim light all day. Researchers will measure sleep quality,…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This study tests whether group sessions that teach stress management skills can lower distress in people with cancer. About 400 adults with cancer who have moderate distress will take part. The program helps patients recognize and reduce stress in their daily lives.

This study tests whether certain mouth rinses or oral medications can prevent or reduce taste changes caused by the drug talquetamab, used to treat multiple myeloma. About 210 participants will be randomly assigned to different preventive treatments. The goal is to find a way to …

This study collects blood stem cells and immune cells from healthy volunteers and patients with primary immune deficiencies or blood disorders. The cells are used in the lab to develop new gene and cell therapies. Up to 850 adults aged 18-70 will participate. The goal is to advan…

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study collects blood, bone marrow, skin, saliva, and stool samples from up to 1,000 healthy volunteers aged 18 and older. The samples will be stored in a database for researchers to compare with samples from people who have myelodysplastic syndromes (MDS), a group of blood d…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…

This study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study asks 3000 teens and young adults (ages 15-39) with cancer, along with their caregivers, to answer survey questions about body image, fertility, and financial stress. The goal is to create better tools to measure quality of life for future patients. Participants include…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This registry collects detailed information from cancer patients treated with proton radiation therapy. Researchers will track treatment plans, side effects, and quality of life over 15 years. The goal is to learn which patients benefit most from this precise form of radiation an…

This study collects bone marrow and blood samples from up to 600 people with mastocytosis, a condition where too many mast cells cause symptoms like itching and bone pain. Researchers will study what makes these cells grow and survive. The goal is to learn more about the disease,…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study investigates whether the health of a patient's immune cells can predict how well they will respond to CAR-T or bispecific antibody treatments for relapsed multiple myeloma. Researchers will analyze blood samples from patients aged 65 and older before they start standar…

This study looks at how a simple monitor called the Pleth Variability Index (PVI) changes during laparoscopic-assisted vaginal hysterectomy. Researchers will track PVI at six key moments when the patient's body position changes, such as tilting the head down or raising the legs. …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study gathers blood and bone marrow samples from 150 adults with myelodysplastic syndrome (MDS), a blood disorder that can turn into acute leukemia. Researchers want to find biological markers that help predict which patients are likely to progress to leukemia. The goal is t…

This study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This Mayo Clinic study is collecting blood samples from 30 cancer patients to create personalized stem cell models. The goal is to understand why some people have severe side effects from cancer therapy while others do not. This is a non-interventional study, meaning no new treat…

This study looks at whether testing lung cancer cells in a lab can predict which drugs will work best for each patient. Researchers will collect fluid from around the lungs of 400 people with lung cancer who need drainage for shortness of breath. They will grow the cancer cells i…

This study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…

This study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This registry will follow 1,000 adults with chronic-phase CML who are taking approved TKIs (like Gleevec or Tasigna) as their first or second treatment. Over 5 years, researchers will track side effects, treatment changes, and patient-reported experiences to understand how these …

This study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…

This observational study examines a specific group of patients with a type of acute myeloid leukemia (AML) that has an NPM1 mutation. Researchers want to see if a particular subset, called APL-like, is linked to early blood vessel problems like bleeding or clots. The study will l…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study follows people with myelodysplastic syndromes (MDS) for up to 20 years to understand how the disease changes over time. Researchers will collect blood, bone marrow, and other samples from 1,100 participants, including healthy donors. The goal is to learn more about MDS…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This study looks at whether we can safely remove the "beta-lactam allergy" label from blood cancer patients who are not truly allergic. By doing so, doctors can use more effective antibiotics. The study will enroll 3,800 hospitalized adults with blood cancers and a reported aller…

This study looks at blood cells from people with chronic myelomonocytic leukemia (CMML) to learn more about how the disease works. Researchers will study specific immune cells, including monocytes and immature granulocytes, to understand why they don't develop normally. The goal …

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study explores whether combining a drug sensitivity test with detailed genetic profiling can help doctors recommend the best treatment for each patient with relapsed or refractory acute myeloid leukemia (AML). Researchers will take extra blood or bone marrow samples from 18 …

This study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal i…

This study looks at blood samples from 350 adults with blood cancer who develop a fever and have very low white blood cells (a condition called febrile neutropenia). The goal is to find patterns of proteins in the blood that can predict if a patient will develop serious complicat…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study is collecting information on side effects from proton therapy in 5,000 adults with many types of cancer. Researchers will track both short-term and long-term side effects and link them to the details of each patient's treatment plan. The goal is to better predict who m…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…

This pilot study is testing whether fecal microbiota transplantation (FMT) — giving processed stool from a healthy donor via enema — is safe and doable in 20 patients with lymphoma or leukemia who are receiving CAR-T therapy or stem cell transplants. The goal is to see if at leas…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study investigates whether changes in the GBA and PSAP genes are more common in people with multiple myeloma or its precursor condition, MGUS. Researchers will compare the frequency of these gene variants in 300 patients against known population databases. The goal is to bet…

This study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…

This observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…

This study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive chang…

This study aims to understand how well the seasonal flu vaccine works in children with blood cancers like leukemia. Researchers will measure the immune response in up to 150 children at St. Jude Children's Research Hospital. The goal is to see if the vaccine triggers enough prote…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study looks at DNA and protein changes in tumor samples from 50 adults with aggressive or metastatic cancer. Researchers aim to find new markers for diagnosis and potential drugs. Participants provide blood, cheek swabs, and tissue from standard biopsies or surgeries.

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will check for long-term side effects and how well the treatment works over 15 years. No new treatment is given—just regular monitoring to meet safety guide…

This study collects blood, bone marrow, and other samples along with health information from up to 1,716 people with non-cancerous blood diseases and their family members. Researchers will analyze the participants' genes to find new genetic causes of these conditions and understa…

This study collects blood and bone marrow samples from 80 adults newly diagnosed with acute myeloid leukemia (AML). Researchers will measure inflammasome activity before and after standard chemotherapy to see if it relates to how well the treatment works. The goal is to better un…

This study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…

This study creates a worldwide registry for people diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a very rare blood cancer. Researchers will collect information on how the disease presents, how it is treated, and what happens to patients over time. The goal …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This early-stage study with 10 adults with acute leukemia looks at how the body absorbs, breaks down, and gets rid of the drug bleximenib. Participants take a radioactive version of the drug so researchers can track it in urine and stool. The goal is to understand the drug's path…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study follows about 300 people with multiple myeloma that has come back or stopped responding to treatment. Researchers will watch how well standard treatments work in real-life settings over 24 months, focusing on response rates, safety, and how patients feel. The goal is t…